CagriSema
Also known as: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog) in development. Aims to provide superior weight loss through dual mechanisms.
Mechanism of Action
Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1.
Research Summary
Phase 2 trials showed up to 17.1% weight loss at 32 weeks, potentially superior to semaglutide alone. Phase 3 trials (REDEFINE program) ongoing for obesity and diabetes.
Research Protocols
Note: Doses from clinical trials
Common Doses
- •Semaglutide 2.4mg + Cagrilintide 2.4mg weekly
Duration
Long-term use expected
Administration
Subcutaneous injection weekly
Side Effects & Considerations
- •GI effects (nausea, vomiting, diarrhea)
- •Expected similar to GLP-1 class
- •Phase 3 will provide more data
References
Want updates on CagriSema research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.